
Liora Schultz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2161222/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine, 2021, 27, 1419-1431.	30.7	273
2	Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. Journal of Clinical Oncology, 2022, 40, 945-955.	1.6	79
3	Driving CAR T cell translation forward. Science Translational Medicine, 2019, 11, .	12.4	61
4	CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma. Blood, 2021, 137, 2321-2325.	1.4	51
5	Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin. PLoS ONE, 2019, 14, e0219547.	2.5	38
6	Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. Blood Advances, 2022, 6, 600-610.	5.2	32
7	Mechanisms of and approaches to overcoming resistance to immunotherapy. Hematology American Society of Hematology Education Program, 2019, 2019, 226-232.	2.5	23
8	Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes. Frontiers in Immunology, 2020, 11, 1985.	4.8	7
9	Abstract CT031: GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas. , 2021, , .		7
10	EPCT-14. GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG. Neuro-Oncology, 2021, 23, i49-i50.	1.2	6
11	CD81 costimulation skews CAR transduction toward naive T cells. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	6
12	Summary of COVIDâ€19 clinical practice adjustments across select institutions. Pediatric Blood and Cancer, 2020, 67, e28411.	1.5	4
13	Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report. , 2020, 8, e001073.		2